In order to bring you the best possible user experience, this site uses Javascript. If you are seeing this message, it is likely that the Javascript option in your browser is disabled. For optimal viewing of this site, please ensure that Javascript is enabled for your browser.
Did you know that your browser is out of date? To get the best experience using our website we recommend that you upgrade to a newer version. Learn more.

Statin use is associated with lower risk of stroke in patients with atrial fibrillation

Atrial Fibrillation

Barcelona, Spain – 16 April 2023:  A region-wide study in more than 50,000 patients with atrial fibrillation has found reduced risks of stroke and transient ischaemic attack in those who started statins within a year of diagnosis compared with those who did not. The findings are presented at EHRA 2023, a scientific congress of the European Society of Cardiology (ESC).1

“Our study indicates that taking statins for many years was even more protective against stroke than short-term use,” said study author Ms. Jiayi Huang, a PhD student at the University of Hong Kong, China.

Atrial fibrillation is the most common heart rhythm disorder, affecting more than 40 million people worldwide.2 Patients with the condition have a five times greater risk of stroke than their peers. Anticoagulant medication is recommended to prevent strokes in those with atrial fibrillation but does not completely eliminate risk. Statin therapy is widely prescribed to lower blood cholesterol and reduce the likelihood of heart attack and stroke. However, the benefit of statins for stroke prevention in patients with atrial fibrillation has been unclear.

This study evaluated the association between statin use and the incidence of stroke and transient ischaemic attack in patients with atrial fibrillation. The researchers used the Hong Kong Clinical Data Analysis and Reporting System to identify all patients with a new diagnosis of atrial fibrillation between 2010 and 2018. Participants were divided into two groups: statin users and non-users. Users had received statins for at least 90 consecutive days during the year after being diagnosed with atrial fibrillation.

The primary outcomes were the combined endpoint of ischaemic stroke or systemic embolism; haemorrhagic stroke; and transient ischaemic attack. Patients were followed until the occurrence of the primary outcomes, death or the end of the study on 31 October 2022.   

A total of 51,472 patients with a new diagnosis of atrial fibrillation were included, of which 11,866 were classified as statin users and 39,606 were non-users. The median age of participants was 75 years and 48% were women. During a median follow up of five years, statin users had a significantly lower risk of all primary outcomes compared to non-users. Statin use was associated with a 17% reduced risk of ischaemic stroke or systemic embolism (hazard ratio [HR] 0.83; 95% confidence interval [CI] 0.78–0.89), a 7% reduced risk of haemorrhagic stroke (HR 0.93; 95% CI 0.89–0.98) and a 15% reduced risk of transient ischaemic attack (HR 0.85; 95% CI 0.80–0.90).

The researchers also found that long-term statin use was associated with greater protection than short-term use. Compared to those taking the medication for between three months and two years, patients using statins for six years or longer had a 43% lower risk of ischaemic stroke or systemic embolism (HR 0.57; 95% CI 0.54–0.61), 44% reduced likelihood of haemorrhagic stroke (HR 0.56; 95% CI 0.53–0.60) and 42% reduced risk of transient ischaemic attack (HR 0.58; 95% CI 0.52–0.64). These associations were consistent regardless of whether or not patients used anticoagulant medication and the type of anticoagulant.

Ms. Huang said: “These data support the use of statins to prevent stroke and transient ischaemic attack in patients with new-onset atrial fibrillation. The findings have important clinical implications particularly given that in atrial fibrillation patients, ischaemic strokes are often fatal or disabling, and have a high risk of recurrence.”



1The abstract ‘Statin use improves the outcomes in patients with atrial fibrillation: A population-based study’ will be presented during the session ‘Atrial Fibrillation - Round 1 - Stroke - OAC’ which takes place on 16 April at 09:40 CEST at Moderated ePosters station 1.
2Hindricks G, Potpara T, Dagres N, et al. 2020 ESC Guidelines for the diagnosis and management of atrial fibrillation developed in collaboration with the European Association of Cardio-Thoracic Surgery (EACTS). Eur Heart J. 2021;42:373–498.

Notes to editor

Authors: ESC Press Office 
Tel: +33 (0)489 872 075
Follow us on Twitter @ESCardioNews 

Funding: The study was supported by Sanming Project Shenzhen.

Disclosures: None.

About the European Heart Rhythm Association

The European Heart Rhythm Association (EHRA) is a branch of the European Society of Cardiology (ESC). Its aim is to improve patients’ quality of life and reduce sudden cardiac death by limiting the impact of heart rhythm disturbances. 

About the EHRA Congress     #EHRA2023
EHRA 2023 is the annual congress of the European Heart Rhythm Association (EHRA) of the European Society of Cardiology (ESC).

About the European Society of Cardiology 

The European Society of Cardiology brings together health care professionals from more than 150 countries, working to advance cardiovascular medicine and help people lead longer, healthier lives.

Information for journalists about registration for EHRA 2023
EHRA 2023 will be held 16 to 18 April at the Fira Gran Via, Hall 8, in Barcelona, Spain and online. Explore the scientific programme.

  • Free registration applies to accredited press.
  • Credentials: A valid press card or appropriate letter of assignment with proof of three recent published articles. Read the ESC media and embargo policy.
  • The ESC Press Office will verify the documents and confirm by email that your press accreditation is valid.
  • The ESC Press Office decision is final regarding all press registration requests.